Anixike Numbing

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the temporary relief of local pain and discomfort associated with the anorectal area.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

For adults and children aged 12 years and older, the recommended application is to the affected area not more than 3 to 4 times daily. It is important to ensure that the application is performed with clean hands and that the affected area is clean and dry prior to administration.

For children under 12 years of age, it is advised to consult a physician before use to determine the appropriate dosage and administration guidelines.

Contraindications

Use of this product is contraindicated in individuals with a known allergy to any of its ingredients.

Additionally, the product should not be applied to the eyes, broken skin, or mucous membranes due to the potential for irritation or adverse reactions. It is also contraindicated for rectal administration using fingers, mechanical devices, or applicators, as this may lead to complications or ineffective use.

Warnings and Precautions

This product is intended for external use only. In the event of accidental ingestion, immediate medical assistance should be sought.

Healthcare professionals should advise patients to avoid application to the eyes, broken skin, or mucous membranes. It is imperative that this product not be introduced into the rectum using fingers or any mechanical device or applicator, as this may lead to adverse effects.

Patients should be instructed to discontinue use and consult a physician if the condition worsens or if symptoms persist beyond 7 days. Additionally, if an allergic reaction to any of the ingredients occurs, or if the symptoms being treated do not subside, it is crucial to seek medical advice.

Monitoring for the development or exacerbation of symptoms such as redness, irritation, swelling, or pain is recommended. If symptoms resolve and then recur within a few days, patients should also be advised to contact their healthcare provider for further evaluation.

Side Effects

Patients using this product should be aware that it is intended for external use only. In clinical practice, it is important to monitor for adverse reactions, particularly if the condition being treated does not improve or worsens.

Participants are advised to discontinue use and consult a healthcare professional if any of the following occur: the condition worsens or does not show improvement within 7 days; an allergic reaction to any of the product's ingredients is suspected; or if the symptoms being treated do not subside. Additionally, patients should seek medical advice if they experience increased redness, irritation, swelling, pain, or any other concerning symptoms.

It is also recommended that patients stop using the product and consult a doctor if symptoms clear up and then return within a few days. These precautions are essential to ensure patient safety and effective management of their condition.

Drug Interactions

There are currently no documented drug interactions associated with the use of this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Anixike Numbing (menthol 5% numbing). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 12 years of age should consult a healthcare professional before use. For adolescents and children aged 12 years and older, the recommended application is to the affected area no more than 3 to 4 times daily.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully considered in these populations to ensure the safety of both the mother and the fetus or infant.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data regarding the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Dosage adjustments may be necessary for patients with reduced renal function. It is important to monitor renal function tests regularly in patients with known kidney problems. Additionally, a reduced dose should be considered for patients with a creatinine clearance of less than 30 mL/min.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in clinical trials for this medication. Consequently, there is no available information regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be warranted based on clinical judgment.

Overdosage

There is currently no specific information available regarding overdosage for this medication. Healthcare professionals are advised to monitor patients closely for any signs of adverse effects or symptoms that may arise from excessive dosing.

In the event of suspected overdosage, it is recommended that healthcare providers initiate supportive care and symptomatic treatment as necessary. Patients should be evaluated for potential complications, and appropriate interventions should be implemented based on the clinical presentation.

For further guidance, healthcare professionals should refer to established protocols and consult relevant toxicology resources.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek medical help immediately if the product is swallowed. It is important to inform patients not to use the product if they have a known allergy to any of its ingredients. For patients who are pregnant or breastfeeding, a discussion with a health professional is recommended prior to use.

Patients should be instructed to avoid applying the product to the eyes, broken skin, or mucous membranes. Additionally, they should be cautioned against inserting the product into the rectum using fingers or any mechanical device or applicator.

Healthcare providers should emphasize the importance of discontinuing use and consulting a doctor if the patient's condition worsens or if symptoms persist beyond 7 days. Patients should also be made aware that they should stop using the product if they experience an allergic reaction to any of its ingredients.

Furthermore, patients should be informed to seek medical advice if the symptoms being treated do not subside, or if they notice any redness, irritation, swelling, pain, or other symptoms that develop or increase. Lastly, patients should be advised to monitor their symptoms and report if they clear up and then return within a few days.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at a temperature range of 15–30°C (59–86°F). Care should be taken to avoid freezing conditions and to prevent exposure to excessive heat, which should not exceed 40°C (104°F). Proper storage conditions are crucial to maintain the integrity and efficacy of the product.

Additional Clinical Information

Patients aged 12 years and older are advised to apply the medication to the affected area no more than 3 to 4 times daily. For children under 12 years of age, it is recommended to consult a doctor regarding the appropriate use and administration of the product. No further information is available regarding laboratory tests, abuse potential, patient counseling, or postmarketing experiences.

Drug Information (PDF)

This file contains official product information for Anixike Numbing, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)